Tuesday, November 29, 2016 9:21:25 AM
Microcurrent therapy uses extremely low-level electrical currents that promote general wellness and alleviate complications associated with certain medical conditions. On a cellular level, the technology stimulates a dramatic increase in ATP (adenosine triphosphate) production and protein synthesis that accelerates healing and increases blood flow. This translates into decreased inflammation, reduced pain, and other beneficial effects for those suffering from a number of potentially serious health conditions.
This approach is a natural alternative to conventional therapies such as pharmaceuticals and surgical interventions. For example, using microcurrent therapies to reduce pain has the potential to reduce the excessive usage of opioid medications, as well as treat conditions for which there are no conventional therapies – such as fibromyalgia or diabetes – where existing standard-of-care options only slightly reduce complications.
In this article, we will look at how Cell MedX Corp. (CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.
A Better Approach
The most common microcurrent therapy is known as a pulsed electrical magnetic field – or PEMF, which is applied to the skin to elicit a cellular response depending on the amplitude, frequency, and waveform. Since the late-1970s, the FDA has approved these kinds of devices to treat everything from non-union fractures to major depressive disorders, although their effectiveness in treating these conditions is widely documented, results tend to vary.
Cell MedX Corp. (CMXC) is pioneering a new microcurrent therapy device called eBalance that uses proprietary software to read the body’s response to the microcurrents being applied, and uses this information to fine-tune a range of electrical frequencies designed to target specific conditions. The company believes that its technology has the potential to address the complications associated with a growing list of medical conditions.
This list of conditions represents multi-billion dollar markets, of which a large percentage of the United States’ population suffers from daily, with few alternative treatment options.
Observational Studies & Clinical Trial
Cell MedX Corp. (CMXC) is initially focusing its clinical protocols on safely studying the effects of its eBalance Pro device on diabetes and related complications. The observations and testimonials resulting from the company’s early observations are currently being reported on Cell MedX’s website on an ongoing basis, but investors will have to wait for the results from its initial observational clinical trials to determine the efficacy profile anticipated for the technology.
Cell MedX plans to begin observational clinical trials early next year with the goal of obtaining Health Canada approval to use eBalance Pro as a medical device for the treatment of diabetes and related complications. While the company is moving to obtain approval from Health Canada, similar activities are under way in Europe and Asia, and as data becomes available management believes it will be able to more readily develop an FDA approval pathway for the U.S. marketplace.
Looking Ahead
Investors interested in the exploding wellness industry may want to take a closer look at Cell MedX Corp. (OTCQB: CMXC) given its unique approach to microcurrent therapies and its potential to address several multi-billion dollar market opportunities. With Canadian observational clinical trials set to begin shortly, the company is building a growing pipeline of catalysts that could drive value for shareholders over the long-term.
For more information, visit the company’s website at http://cellmedx.com/
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.’s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies.
Recent CMXC News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/06/2024 09:49:24 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/22/2024 09:38:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 05:48:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 11:08:43 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 08:29:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 08:36:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 08:27:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:02:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/16/2023 09:20:06 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 09/07/2023 09:00:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/01/2023 09:18:25 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 08/29/2023 09:20:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/29/2023 09:10:35 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM